Articles

Click on an article below to view a “medicine map” of its findings.

• Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
  van der Vaart T,Plasschaert E,Rietman AB,Renard M,Oostenbrink R,Vogels A,de Wit MC,Descheemaeker MJ,Vergouwe Y,Catsman-Berrevoets CE,Legius E,Elgersma Y,Moll HA
  The Lancet. Neurology 2013 Nov 1112delete


• Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1.
  Chabernaud C,Mennes M,Kardel PG,Gaillard WD,Kalbfleisch ML,Vanmeter JW,Packer RJ,Milham MP,Castellanos FX,Acosta MT
  Neuroscience letters 2012 Apr 25 1515delete


• Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1.
  Mainberger F,Jung NH,Zenker M,Wahlländer U,Freudenberg L,Langer S,Berweck S,Winkler T,Straube A,Heinen F,Granström S,Mautner VF,Lidzba K,Mall V
  BMC neurology 2013 Oct 2 13delete


• Influence of cortical synaptic input on striatal neuronal dendritic arborization and sensitivity to excitotoxicity in corticostriatal co-culture.
  Buren C,Tu G,Parsons MP,Sepers MD,Raymond LA
  Journal of neurophysiology 2016 Apr 27 delete


• A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.
  Bearden CE,Hellemann GS,Rosser T,Montojo C,Jonas R,Enrique N,Pacheco L,Hussain SA,Wu JY,Ho JS,McGough JJ,Sugar CA,Silva AJ
  Annals of clinical and translational neurology 2016 Apr 43delete